Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Doxorubicin Stories

2011-03-02 06:12:00

BEVERLY, Mass., March 2, 2011 /PRNewswire/ -- Cellceutix Corporation (Pink Sheets: CTIX) today announced that it has received more data on Kevetrin(TM), the Company's flagship compound for the treatment of cancers. Analysis of the latest research shows Kevetrin(TM) is non-genotoxic, contrary to the majority of currently available chemotherapeutic drugs. Genotoxic drugs affect nucleic acids and alter their function. These drugs may directly bind with DNA or may indirectly lead to DNA damage...

2010-12-10 00:00:58

MM-111 first-in-human phase 1/ 2 and pharmacologic study in patients with advanced refractory HER2-Positive (HER2+) cancers. MM-302 pre-clinical safety and activity study of anthracycline delivery to HER2-Positive (HER2+) tumors. Cambridge, MA (Vocus/PRWEB) December 08, 2010 Merrimack Pharmaceuticals, Inc. announced today that it will present MM-111 Phase 1 clinical data at the 33rd Annual San Antonio Breast Cancer Symposium, as well as pre-clinical data on MM-302, a HER2+ tumor...

2010-12-08 07:00:00

BURLINGTON, Mass., Dec. 8, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive....

2010-12-06 00:30:00

SEATTLE, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("the Company") (Nasdaq and MTA: CTIC) today announced new pixantrone end of study ("EOS") follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application (the "MAA") currently under review by the European Medicines Agency ("EMA"). The end-of-study results showed continued improvement in the trial's primary and secondary...

2010-12-03 00:30:00

SEATTLE, Dec. 3, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application ("NDA") to treat relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL"). CTI had requested accelerated approval of its pixantrone NDA for...

2010-12-01 00:30:00

SEATTLE, Dec. 1, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present end of study results for the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") at the 52nd Annual Meeting of the American Society of Hematology on Sunday, December 5, 2010 in Orlando, Florida. The...

2010-11-18 05:15:00

Encouraging trend observed in overall survival with limited side-effects QUEBEC, Nov. 17 /PRNewswire/ - Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer. The trial was conducted by the German AGO Study Group and centers in Bulgaria. The presentation was made by Prof. Gunter Emons, Chairman, Department of Obstetrics & Gynaecology...

2010-11-18 00:30:00

SEATTLE, Nov. 18, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CTI's Marketing Authorization Application ("MAA") seeking approval for Pixuvri(TM) (pixantrone dimaleate) for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") was validated and accepted for review by the European Medicines Agency ("EMA"). Validation indicates that the application is complete and that the EMA's...

2010-11-17 00:30:00

SEATTLE, Nov. 17, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the European Medicines Agency ("EMA") approved CTI's Pixuvri (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for the treatment of lymphoid malignancies and solid tumors in children between the ages of six months and 18 years. Previously, the Pediatric Committee (the "PDCO") of the EMA adopted an opinion agreeing to the PIP and a deferral of the initiation of the...

2010-11-16 22:11:52

Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared to patients who received treatment with doxorubicin alone, according to a study in the November 17 issue of JAMA. "Hepatocellular [liver] carcinoma (HCC) is the sixth most common malignancy worldwide, with approximately 600,000 new cases per year. Patients with...